Prec

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the XXIstCongress of the International Society on Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy

MISSISSAUGA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced that a study presented by investigators from KinkiUniversity School of Medicine and Kyoto University at the 11thmeeting of The Japanese Association for Molecular Target Therapy ofCancer...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%efficacy for prevention of cervical cancer and precancerous lesionsassociated with the human papillomavirus (HPV) types targeted bythe vaccine, conclude authors of an Article published early Onlineand in the upcoming issue of The Lancet. HPV types 16 and 18 account for 70% or morecases of cervical cancer worldwi...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of twoposters at the XIth Annual International Myeloma Workshop beingheld in Kos, Greece from June 25-28th, 2007. The meeting highlightsimportant advances made in the biology and treatment of multiplemyeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) geneexpression profil...

ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results demonstrating that ACE-011, anovel anabolic bone agent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myel...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that data from a preclinicalstudy of trodusquemine (MSI-1436) for the treatment of obesity werepresented during the American Diabetes Association (ADA) 67thScientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz,Genaera research scientist and lead author of Abstract #1801-P,present...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that it will present a posteron trodusquemine (MSI-1436), its novel anti-obesity compound,during the American Diabetes Association (ADA) 67th ScientificSessions, June 22 to 25 in Chicago. The abstract, # 1801-P, is titled, "Trodusquemine is a MultiplePathway Inhibitor that Causes Diffe...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers atMolecular Insight Pharmaceuticals today announced the presentationof preclinical data on MIP-1072, a radiolabeled, small moleculemolecular imaging pharmaceutical in development for diagnosis andstaging of prostate cancer at the 54th annual meeting of theSociety of Nuclear Medicine (SNM) in Washington, D.C. MIP-1072 isone of two...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular InsightPharmaceuticals, Inc. (NASDAQ: MIPI) announced today that thecompany will present the results of several preclinical studies atthe 54th annual meeting of the Society of Nuclear Medicine (SNM) inWashington, D.C. The presentations include data on Azedra(TM)(Ultratrace (131)I-MIBG), the company's clinical-stage, targetedradiothe...

EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announced the presentation of preclinical results for its Aurorakinase - angiogenesis inhibitor, ENMD-981693. The data werepresented during oral and poster presentations by EntreMedscientists at the 2n...

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in Preclinical Studies

LUCCA, ITALY, ­ May 14, 2007-Acceleron Pharma, Inc., abiopharmaceutical company developing therapeutics for the treatmentof musculoskeletal, metabolic and cancer-related diseases, todayannounced results of a preclinical study with ACE-031 thatdemonstrated the ability of the compound to increase muscle massand strength in normal mice and in murine models of musculardystrophy. ACE-031...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X BiotechnologiesInc. announced today that a report published in the journal Blooddemonstrated that its lead compound, obatoclax (GX15-070), inducedcell death in vitro in Mantle Cell Lymphoma (MCL) cell lines andprimary cells from 11 MCL patients. Obatoclax (GX15-070) is a smallmolecule specifically designed to inhibit all relevant members oft...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results of a preclinical study withACE-031 that demonstrated the ability of the compound to increasemuscle mass and strength in normal mice and in murine models ofmuscular dystrophy...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

The research, done in collaboration with the Centro deInvestigación Médica Aplicada (CIMA) at theUniversity of Navarra, Pamplona, Spain, is being presented atPorphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam MolecularTherapeutics BV (AMT), a leader in the field of human gene therapy,will today present...

Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgen's INGN 241

AUSTIN, Texas--(BUSINESS WIRE)--Apr 25, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) today announced the publication ofnew preclinical data describing how an intrinsic cell survivalpathway impacts the anticancer activity of INGN 241. Inhibition ofthis pathway, known as NF-kB, enhanced the tumor killing effects ofINGN 241 in cell culture and in preclinical models of human tumors.Researche...

ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)

Results Indicate Bioequivalent Pharmacokinetics With Reduced Riskof Hypersensitivity Reactions With ANX-514 SAN DIEGO, April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,today announced positive results from...

Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause ofGenetic Disorders and Restores Protein Function SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- Newpreclinical data published online in the current edition of thejournal Nature show that PTC124, an investigational new drugdesigned to bypass nonsense mutations, was efficacious in apreclinical model of Duchenne muscular...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

- New Study Demonstrated the Clinical Potential of Peregrine'sUnique Selective Anti-VEGF Antibodies, Which Were as Effective asAvastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. , a clinical stagebiopharmaceutical company developing targeted monoclonal antibodiesfor the treatment of cancer and hepatitis C virus infect...

Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced that newpreclinical research demonstrating a role in chronic inflammatoryautoimmune disease for High Mobility Group Box-1 protein (HMGB1), apro-inflammatory mediator and nuclear DNA-binding protein, will bepublished in the May 2007 issue of Nature Immunology. Thepublication demonstrat...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/--EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of preclinical results for MKC-1,its novel cell cycle inhibitor. The data were presented by EntreMedscientists at the American Association for Cancer Research (AACR)Ann...

Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. todayannounced data from a preclinical study in which BiTE(R) moleculestargeting carcinoembryonal antigen (CEA) were shown to preventsubcutaneous tumor growth and formation of lung metastases. Anestablished marker for tumor progression, CEA is frequentlyexpressed on breast,...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

HAYWARD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated today presented preclinical data on itsproprietary nuclear export inhibitors (NEI) showing induction ofpotent, fast-acting and long-lasting anticancer activity with ahigh degree of tolerability in multiple human tumor xenograftcancer models. Kosan's NEIs are potent, specific inhibitors of CRM1,...

Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

Bcl-2 Antagonist shown to be therapeutically effective in amouse model of Chronic Lymphocytic Leukaemia COPENHAGEN, 18 April 2007 - Santaris Pharma, the Danishbiopharmaceutical company developing RNAi drugs, yesterdaypresented encouraging data at the American Association for CancerResearch Annual Meeting in Los Angeles, showing that SPC2996, theCompany's RNA Antagonist of Bcl-2, is...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

NEW YORK--(BUSINESS WIRE)--Apr 18, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) announced data from preclinical evaluation of thecompany's drug candidate INNO-206, a doxorubicin prodrug fortreatment of a variety of tumor types. Researchers found thatINNO-206, a form of doxorubicin that attaches to circulatingalbumin and becomes activated once located at the tumor site, ismuch better to...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...

Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - IderaPharmaceuticals, Inc. (AMEX: IDP) today announced two presentationsof data for two new potential applications in oncology of its novelagonists of Toll-like receptor 9 (TLR9) at the Annual Meeting ofthe American Association for Cancer Research (AACR) being held inLos Angeles, CA, April 14-18, 2007. The first presentation covereda preclin...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with itsBruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - GeminX today announced the presentation of positive preclinical datafrom a study of its lead compound, GX15-070 (obatoclax), in infantacute lymphoblastic leukemia (ALL). The study was discussed in anoral presentation at the Annual Meeting of the American Associationfor Cancer Research (AACR). According to the study, GX15-070demons...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...

Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells

Poster Presentation on April 17, 2007 at AACR SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- AnadysPharmaceuticals, Inc. presented data from an in vitro study showingthat the active metabolite of ANA773 promotes natural killer (NK)cell-mediated anti-tumor response by inducing cytokine secretion,cytolysis of tumor cells and enhanced antibody-dependent cellularcytotoxicity (ADCC), during a p...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood VesselDensity and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hepatitis Cvirus (HCV) infection, today announced that p...